CD8+ T cells are known to play a major role in regulating immune functions under normal and desease conditions. In this study a radioligand binding assay was used to quantitate histamine type II (H2) receptors on activated T cells. The objective was to examine the expression of H2 receptors on T cells during activation with interleukin-2 (IL-2) and treatment with cimetidine. Activated suppressor T cells induced by concanavalin A + IL-2 showed a significant (p < 0.01) increase in H2 receptors compared to the control nonactivated T cells. The T cells expressing the H2 receptors were identified as CD8+ cells; those among them that had an enhanced level of H2 receptors were identified as CD25+. Treatment of activated suppressor cells with the H2 receptor antagonist cimetidine at a concentration of 10––5M significantly reduced the number of H2 receptors. Suppressor cells induced by Con A + IL-2 were able to suppress both IgG and IgM production that was reversible with cimetidine. Incubation of lymphocytes with 50 U/ml IL-2 alone in 3-day culture significantly (p < 0.005) enhanced H2 receptor expression. These studies demonstrate that activated suppressor T cells that are CD8+CD25+ have enhanced levels of H2 receptors and can be modulated by cimetidine.

Letters| October 16 2012 Limbic Encephalitis due to Pancreatic Cancer Subject Area: Oncology Alois J. Schiefecker; Alois J. Schiefecker aDepartment of Neurology, Kliniken Südostbayern – Klinikum Traunstein, Germany bDepartment of Neurology, Innsbruck Medical University, Austria Search for other works by this author on: This Site PubMed Google Scholar Rudolf Kreidenhuber; Rudolf Kreidenhuber aDepartment of Neurology, Kliniken Südostbayern – Klinikum Traunstein, Germany Search for other works by this author on: This Site PubMed Google Scholar Dragana Milankovic-Eberl; Dragana Milankovic-Eberl aDepartment of Neurology, Kliniken Südostbayern – Klinikum Traunstein, Germany Search for other works by this author on: This Site PubMed Google Scholar Thorleif Etgen; Thorleif Etgen aDepartment of Neurology, Kliniken Südostbayern – Klinikum Traunstein, Germany cDepartment of Psychiatry and Psychotherapy, Technische Universität München, Germany Search for other works by this author on: This Site PubMed Google Scholar Georg Rieder Georg Rieder aDepartment of Neurology, Kliniken Südostbayern – Klinikum Traunstein, Germany Search for other works by this author on: This Site PubMed Google Scholar Onkologie (2012) 35 (11): 698–699. https://doi.org/10.1159/000343592 Article history Published Online: October 16 2012 Content Tools Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Citation Alois J. Schiefecker, Rudolf Kreidenhuber, Dragana Milankovic-Eberl, Thorleif Etgen, Georg Rieder; Limbic Encephalitis due to Pancreatic Cancer. Onkologie 1 November 2012; 35 (11): 698–699. https://doi.org/10.1159/000343592 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsOnkologie Search Advanced Search Keywords: Anti-Hu antibodies, Limbic encephalitis, Paraneoplastic diseases, Pancreatic cancer, HuD, Paraneoplastic encephalitis, Paraneoplastic limbic encephalitis This content is only available via PDF. 2012Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Article PDF first page preview Close Modal You do not currently have access to this content.